SAVA Cassava Sciences
- 21.730
- +0.990+4.77%
- 21.750
- +0.020+0.09%
Cassava Sciences News
Cassava Sciences | 8-K: Redemption Date Announced for Warrants
Cassava Sciences | DEF 14A: Definitive information statements
Cassava Sciences | 8-K: Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
Cassava Sciences | 8-K: No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
Cassava Sciences | 8-K: Entry into Material Definitive Agreements
Cassava Sciences | 8-K: Current report
Cassava Sciences | 8-K: Current report
Cassava Sciences | 8-K: Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
Cassava Sciences | 8-K: Current report
Cassava Sciences | 8-K: Cassava Sciences Reports Q2 2023 Financial Results And Operating Updates
Cassava Sciences | 8-K: Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer's Disease
Cassava Sciences | 8-K: Submission of Matters to a Vote of Security Holders
Cassava Sciences | 8-K: Cassava Sciences Terminates Sales Agreement With Svb And Enters Into Capital On Demand™ Sales Agreement With Jonestrading Institutional Services Llc
Cassava Sciences | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Cassava Sciences | 8-K: Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
Cassava Sciences | DEF 14A: Definitive proxy statements
Cassava Sciences | 8-K: Current report
Cassava Sciences | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Cassava Sciences | 8-K: Cassava Sciences confirms JP Morgan as major merchant bank and has no financial exposure to SVB and Silvergate Bank
Cassava Sciences | 8-K: Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
Analysis
Price Target
No Data
